logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • Design Thinking – February 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs

Advertise on Slator! Download the 2021 Online Media Kit Now

  • Slator Market Intelligence
  • Slator Advertising Services
  • Slator Advisory
  • Login
Search
Generic filters
Exact matches only
Advertisement
Impact of China’s New Medical Device Directives on Translation

4 years ago

October 26, 2016

Impact of China’s New Medical Device Directives on Translation

Demand Drivers ·

by Marion Marking

On October 26, 2016

4 years ago
Demand Drivers ·

by Marion Marking

On October 26, 2016

Impact of China’s New Medical Device Directives on Translation

The China Food and Drug Administration (CFDA) released two new directives within 10 days of each other as September drew to a close. One had to do with additional document (dossier) requirements for registering medical devices in the Chinese market; the other, a new list of medical devices exempt from clinical trials.

According to the dossier directive, released September 20, 2016, an exporter with a Class II or III medical device must now submit to the CFDA not only the original registration dossier, but also photocopies, PDF soft copies, and “a declaration that the photocopies and PDF are identical to the original documents,” said Sam Hsia, Director of Clinical Operation for Medical Device at business logistics company Fountain Medical Development (FMD).

Hsia told Slator this additional requirement will most likely not substantially affect the number of documents to be translated into Chinese, as the required dossiers are simply scanned copies of the original documents. The new dossier requirement takes effect from November 1, 2016.

Advertisement

Regarding the clinical trial exemption directive, effective from September 30, 2016, Hsia said he does not expect it to impact the volume of documents to be translated either, “because it will not change the requirements and is just a summary of previous changes.”

These most recent CFDA clinical trial exemptions cover both Class II and III medical devices; which brings the total of Class II exempt devices to 276 (e.g., devices for assisted reproduction, plastic surgery) and Class III to 92 (e.g., devices for blood processing, bypass).

The latest CFDA clinical trial exemptions take effect from September 30, 2016; the new dossier requirement, from November 1, 2016

Landon Lack, CEO of China MedConnect, on the other hand, sees the possibility of an increased demand for translation. Lack pointed out that “documentation (and therefore translation) requirements will increase and possibly very significantly if a clinical trial requirement—or making the case to avoid it—invariably increases the required documentation and associated translation.”

China MedConnect is an agent for foreign medical device companies operating in the Chinese market. In a previous article on Slator, Lack said the greatest impact on US medical device companies came from the closing of the loophole that enabled Class III high-risk devices to avoid a CFDA clinical trial.

The loophole was used by all US and Europe medical device manufacturers, according to Lack, and allowed a manufacturer who had already registered any device (even Class I) to avoid a clinical trial with a new device registration and all the accompanying documents translated into Chinese along with it.

Asked whether China was relaxing medical device regulations or closing loopholes, Hsia replied, “For Class I, relaxing. For Class II and III, [the CFDA is] mostly closing loopholes.”

TAGS

Chinamedical devicemedical translationregulatory
SHARE
Marion Marking

By Marion Marking

Slator consultant and corporate communications professional who enjoys exploring Asian cities.

Advertisement

SUBSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

SUBSCRIBE

SlatorSweepSlatorPro
ResearchRFP CENTER

PUBLISH

PRESS RELEASEDIRECTORY LISTING
JOB ADEVENT LISTING

Bespoke advisory including speaking, briefings and M&A

SLATOR ADVISORY
Advertisement

Featured Reports

See all
Slator 2020 Language Industry M&A and Funding Report

Slator 2020 Language Industry M&A and Funding Report

by Slator

Slator 2021 Data-for-AI Market Report

Slator 2021 Data-for-AI Market Report

by Slator

Slator 2020 Medtech Translation and Localization Report

Slator 2020 Medtech Translation and Localization Report

by Slator

Pro Guide: Sales and Marketing for Language Service Providers

Pro Guide: Sales and Marketing for Language Service Providers

by Slator

Press Releases

See all
Rheinschrift Language Services – Strategic Improvements and Workforce Expansion in 2021

Rheinschrift Language Services – Strategic Improvements and Workforce Expansion in 2021

by Rheinschrift Language Services

Memsource Acquires Phrase

Memsource Acquires Phrase

by Memsource

Across Systems will be part of the Volaris Group

Across Systems will be part of the Volaris Group

by Across Systems GmbH

Upcoming Events

See All
  1. Memsource MT Post-Editing Pricing Models Webinar

    Pricing Models for MT Post-Editing Workshop

    by Memsource

    · February 3

    Hear a panel of innovative localization professionals share different approaches for MT post-editing pricing.

    More info FREE

Featured Companies

See all
Text United

Text United

Memsource

Memsource

Wordbank

Wordbank

Protranslating

Protranslating

Seprotec

Seprotec

Versacom

Versacom

SDL

SDL

Smartling

Smartling

Lingotek

Lingotek

XTM International

XTM International

Smartcat

Smartcat

Translators without Borders

Translators without Borders

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Advertisement

Popular articles

Why Netflix Shut Down Its Translation Portal Hermes

Why Netflix Shut Down Its Translation Portal Hermes

by Esther Bond

Top Language Industry Quotes of 2020

Top Language Industry Quotes of 2020

by Monica Jamieson

The Slator 2020 Language Service Provider Index

The Slator 2020 Language Service Provider Index

by Slator

SlatorPod: The Weekly Language Industry Podcast

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Subscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2021 Slator. All rights reserved.

Sign up to the Slator Weekly

Join over 13,000 subscribers and get the latest language industry intelligence every Friday

Your information will never be shared with third parties. No Spam.